Price Alert

(BIAF)

NASDAQ: BIAF · Real-Time Price · USD

0.29

0.01 (2.04%)

At close: Jun 09, 2025, 3:59 PM

2.04% (1D)

Bid	0.26
Market Cap	8.16M
AUM	n/a
NAV	n/a
EPS (ttm)	-0.71
PE Ratio (ttm)	-0.40
Shares Out	28.46M
Inception Date	Invalid Date

Ask	0.3
Volume	696,876
Open	0.29
Previous Close	0.28
Day's Range	0.28 - 0.29
52-Week Range	0.16 - 2.99
Holdings	n/a
Expense Ratio	undefined%

About BIAF

A detailed description of the company is not yet available.

Asset Class undefined

Ticker Symbol BIAF

Inception Date Invalid Date

Provider undefined

Website Fund Home Page

Exchange NASDAQ

Why Price Moved

3 months ago

+46.84%

BioAffinity Technologies shares are trading higher... Unlock content with Pro Subscription

4 months ago

-44.5%

BioAffinity Technologies shares are trading lower after the company announced the pricing of its $3.25 million offering.

News

3 months ago · businesswire.com

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces new patent for method of selectively killing cancer by targeting two specific receptors on the cell membrane.

3 months ago · zacks.com

BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline

bioAffinity's first-quarter 2025 results show CyPath Lung sales growth and cost cuts despite a drop in total revenues and a wider quarterly net loss.

4 months ago · businesswire.com

bioAffinity Technologies Reports First Quarter 2025 Results

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports first-quarter 2025 results.

4 months ago · businesswire.com

bioAffinity Technologies Announces Closing of $3.25 Million Offering

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today closed the previously announced best efforts offering of securities for aggregate gross proceeds of $3.25 million.

4 months ago · businesswire.com

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces the pricing of a best efforts offering of securities for aggregate gross proceeds of $3.25 million.

4 months ago · businesswire.com

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies is implementing efficiency measures for CyPath Lung that streamline lab processing and data acquisition and reduce lab costs.

5 months ago · zacks.com

BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues

bioAffinity witnesses record 2024 revenues, driven by CyPath Lung adoption, Medicare coverage and strategic expansion across healthcare networks.

5 months ago · businesswire.com

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (BIAF) releases financial results for 2024.

5 months ago · businesswire.com

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies' CyPath Lung test uncovered a hidden second primary lung cancer in a patient who had been treated for lung cancer earlier.

5 months ago · businesswire.com

Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--In another case study, CyPath® Lung helped physicians identify and treat a recurrence of breast cancer in a high-risk patient.